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ABSTRACT
Despite evidence of increased endometrial cancer (EC) risk in obese women, the 
impact of obesity on clinical and histological phenotype is poorly understood. This 
study explored abdominal fat volumes and fat distribution quantified by computed 
tomography (CT), in relation to tumor characteristics and outcome. 227 EC patients 
with preoperative abdominal CT scans were included. Total abdominal fat volume 
(TAV), subcutaneous abdominal fat volume (SAV) and visceral abdominal fat volume 
(VAV) were quantified, and visceral fat percentage calculated (VAV%=[VAV/TAV]
x100). Waist circumference (WC) and liver density (LD) were measured, and body 
mass index (BMI) calculated. Data for estrogen, progesterone and androgen receptor 
(ERα/PR/AR) expression by immunohistochemistry were available for 149 tumors, and 
global gene expression data for 105 tumors. High BMI, TAV, SAV, VAV and WC, and low 
LD, were associated with low grade endometrioid tumors and PR and AR positivity (all 
p≤0.03). High VAV% was associated with high age (p<0.001), aneuploidy (p=0.01) 
and independently predicted reduced disease-specific survival (HR 1.05, 95% CI 
1.00-1.11, p=0.041). Tumors from patients with low VAV% showed enrichment of 
gene sets related to immune activation and inflammation. In conclusion, high VAV% 
independently predicts reduced EC survival. Tumors arising in patients with low VAV% 
show enrichment of immune and inflammation related gene sets, suggesting that the 
global metabolic setting may be important for tumor immune response.
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INTRODUCTION
Excess body weight, typically measured as high 
body mass index (BMI; kg/m2), is a major risk factor for 
endometrial cancer (EC) development [1, 2]. Despite the 
well-known association between obesity and increased 
risk of various cancers, the underlying mechanisms 
linking obesity to cancer development are complex, and 
only partly understood [3, 4]. Unopposed endogenous 
estrogen signaling is known to promote EC development 
[5], which could explain some of the risk attributed to 
obesity since estrogens are primarily produced in the 
adipose tissue after menopause [3]. However, obesity 
is an independent risk factor for both type 1 and type 2 
EC [6], although the latter is generally considered less 
hormone dependent [7]. Other putative mechanisms 
involved in obesity-related carcinogenesis include 
increased inflammatory signaling through various 
mediators, and increased levels of insulin and insulin 
like growth factor 1 (IGF1) [3-5, 8], thought to promote 
proliferation, production of anti-apoptotic signals, local 
inflammation and angiogenesis.
BMI as a surrogate marker for obesity has met 
considerable criticism. Although easily calculated 
and monitored in the clinic, it is a crude parameter 
not distinguishing between fat and muscle mass [9]. 
Furthermore, neither BMI nor other anthropometric 
measures including waist circumference or hip/waist 
ratio account for the localization of abdominal fat 
deposits in the subcutaneous or visceral compartments. 
Individuals with high quantities of visceral fat, due to 
increased mesenteric, omental and retroperitoneal fat 
storage, carry an increased risk of cardiovascular disease 
and type 2 diabetes [10]. They are also at higher risk 
of developing breast-, colorectal- and esophageal cancer 
[11], compared to individuals with less visceral fat. The 
visceral fat exerts distinct endocrine activity, which 
is thought to contribute to its increased pathogenic 
potential [10]. There is also emerging evidence that 
the fat distribution pattern may be associated with 
survival and therapeutic response in several cancer 
types, i.e. malignant melanomas, breast-, colorectal- 
and esophageal cancers [12-15]. Assessment of the 
abdominal fat compartments by abdominal computed 
tomography (CT) or magnetic resonance imaging (MRI) 
has been shown to be both feasible and reliable [16-
18]. Furthermore, abdominal CT and MRI may allow 
estimation of hepatic steatosis [19], considered to be 
closely linked to obesity [3, 20].
Only a few studies have previously explored the 
visceral and subcutaneous fat distribution in relation to 
clinicopathological characteristics in EC [21, 22]. One 
study suggested an association between a high proportion 
of visceral fat and aggressive clinical features, including 
lymph node metastasis and extrauterine disease [22]. 
However, none of these studies reported volumetric 
estimates of the abdominal fat compartments, nor included 
patient survival data.
This study aimed to explore CT-quantified 
abdominal fat volumes and fat distribution, as well 
as CT-assessed abdominal circumference and hepatic 
attenuation in relation to BMI, clinicopathological 
features and survival in a large endometrial cancer 
patient series. Furthermore, we aimed to explore the CT-
derived measures in relation to molecular markers in 
corresponding tumor tissue.
RESULTS
Intraabdominal fat volumes are correlated with 
BMI
The clinicopathological characteristics of the patient 
series (n=227) are summarized in Table 1. The mean age 
was 67 years (range 30-89). The correlations between 
BMI and the CT-assessed obesity variables (subcutaneous 
abdominal fat volume, SAV; visceral abdominal fat 
volume, VAV; total abdominal fat volume, TAV; [VAV/
TAV]x100, VAV%; waist circumference, WC; and liver 
density, LD) are given in Table 2. All the CT estimated 
fat volumes (TAV, VAV and SAV), as well as WC (Figure 
1A and 1B), were strongly positively correlated with 
patient BMI and with each other (Table 2), whereas 
LD was strongly negatively correlated with all obesity 
markers (Table 2, Supplementary Figure 1). The visceral 
fat percentage (VAV%) was not correlated with BMI, WC 
or TAV, but was weakly negatively correlated with LD 
(Table 2).
Obesity is associated with low-grade endometrial 
cancer and PR and AR expression, but not ERɑ 
expression
High values for the CT estimates reflecting obesity, 
i.e. TAV, VAV, SAV and WC, and high BMI, were all 
significantly associated with low-grade endometrioid 
subtype, and positivity for progesterone (PR) and 
androgen (AR) receptor in tumor tissue (Table 3). No 
association was observed between estrogen receptor 
alpha (ERɑ) expression and the same obesity measures 
(Table 3). Exploring the association between loss of 
hormone receptors with total abdominal fat volume, an 
incremental decrease in fat volume was noted for patients 
with loss of one, two and all three receptors (p=0.003; 
Figure 2). A similar pattern was seen when analyzing 
endometrioid tumors only (p=0.02), however the tendency 
was stronger in the subgroup of grade 3 tumors (n=21, 
p=0.041) compared to grade 1-2 tumors (n=94, p=0.19, 
data not shown). BMI and subcutaneous fat volume were 
also significantly higher in younger patients (p=0.04 and 
p=0.02, respectively; Table 3). In contrast, VAV% was 
significantly higher in patients with high age (p<0.001) 
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Table 1: Clinicopathological characteristics of 227 included endometrial cancer patients
n (%)
Primary treatment
 HBSO 221 (97)
 Curettage/palliative surgery 6 (3)
FIGO stage
 Stage I 180 (79)
 Stage II 21 (9)
 Stage III 21 (9)
 Stage IV 5 (2)
Histological subtype & grade (n=225)
 Endometrioid grade 1-2 152 (68)
 Endometrioid grade 3 32 (14)
 Non-endometrioid 41 (18)
Menopausal status
 Pre/perimenopausal 20 (9)
 Postmenopausal 207 (91)
Type II diabetes
 No 206 (91)
 Yes 21 (9)
Parity
 Nulliparous 28 (12)
 ≥ 1 199 (88)
Lymphadenectomy
 Pelvic 154 (68)
 Pelvic + para-aortic 24 (11)
 No 49 (22)
Lymph node metastasis (n=178)
 No 159 (99)
 Yes 19 (11)
Ploidy status (n=119)
 Diploid 94 (79)
 Aneuploid 25 (21)
BMI (n=226)
 Mean (SD) 27.9 (5.8)
Age
 Mean (SD) 66.9 (11.2)
Abbreviations: BMI: Body mass index; FIGO: International federation of gynecology and obstetrics; HBSO: Hysterectomy 
with bilateral salpingo-oophorectomy; n: number of patients in each category; SD: Standard deviation.
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and aneuploid tumors (p=0.01). Subset analysis in the 
endometrioid subgroup (n=186), revealed a similar overall 
pattern with low grade disease and PR/AR, but not ERɑ, 
positivity significantly associated with higher BMI, WC, 
VAV, SAV, TAV and LD (Supplementary Table 1).
A high percentage of visceral fat is associated 
with reduced endometrial cancer survival
None of the volumetric CT variables (TAV, 
VAV or SAV), BMI, WC or LD (Figure 1A and 1B, 
Supplementary Figure 1) were significantly associated 
with survival in univariable Cox analysis (data not 
shown). However, increasing VAV% was significantly 
associated with reduced survival in the univariable Cox-
model (HR 1.07, 95% CI 1.03 – 1.12, p=0.001; Table 4), 
also visualized in the Kaplan-Meier plot where patients 
with VAV% above median (≥37%) had significantly 
reduced survival (p=0.005, Figure 1C). The same 
trend was found in analyses stratified for BMI above 
and below 30, respectively (p=0.04 for both groups; 
Supplementary Figure 2A and 2B). When adjusting 
for the known prognostic variables age, FIGO stage, 
histological subtype and grade in the Cox model, VAV% 
had independent prognostic impact (HR 1.05, 95% CI 
1.00 – 1.11, p=0.041), whereas age did not (p=0.40) 
(Table 4). There were no observed differences in the 
received surgical treatment (p=0.21) or adjuvant therapy 
(p=0.39) between patients with high versus low VAV% 
(data not shown).
Global transcriptional analysis suggests 
increased immunogenic and inflammatory 
signaling in tumors arising in low VAV% context
Due to the observed survival differences, we 
further explored differences in gene expression patterns 
between tumors arising in a metabolic environment 
characterized by low versus high visceral fat percentage 
(VAV%). GSEA was performed, on the total series, and 
on endometrioid tumors separately. The tumors from 
patients with VAV% below median (<37%) showed 
enrichment of gene sets related to immune activation 
(e.g. immune response, T-cell activation, lymphocyte 
activation, response to bacterium) and inflammatory 
pathways (e.g. inflammatory response, interferon gamma 
response, cytokine binding), both when all histological 
types were included (Figure 1D, Supplementary Table 
2), and in the subgroup of endometrioid tumors only 
(Supplementary Table 3). In tumors with high VAV%, 
false discovery rate (FDR) values tended to be higher, and 
thus no significantly enriched gene sets were identified in 
these tumors.
DISCUSSION
Despite consistent evidence of increased 
endometrial cancer risk in obese women [1, 2], the 
underlying biological relation between obesity and the 
observed clinical and histopathological phenotypes in 
endometrial cancer is poorly understood. The present 
large endometrial cancer study links abdominal 
CT estimates reflecting obesity to a less aggressive 
histological phenotype, and suggests a negative 
prognostic impact of high visceral fat percentage 
(VAV%). Furthermore, low VAV% was linked to 
enrichment of gene sets regulating immunogenic and 
inflammatory response in the tumors. Thus, our data 
supports both a pathogenic and prognostic role of the 
metabolic environment induced by obesity in endometrial 
cancer, and suggests that transcriptional alterations in 
genes regulating immune- and inflammatory responses in 
the tumors may be linked to the metabolic environment 
in which the tumor arises.
This study shows that volumetric CT 
assessment of abdominal fat compartments and waist 
Table 2: Correlations (Spearman rho, ρ) between BMI and CT estimates of obesity in 227 endometrial cancer 
patients
Mean ± SD (range), unit BMI WC TAV VAV SAV VAV%
BMI1 27.9 ± 5.8 (15.6 - 50.0), kg/m2
Waist circumference (WC, L3-L4 level) 95.7 ± 13.9 (63 - 135), cm 0.90**
Total abdominal fat volume (TAV) 9,534 ± 4,599 (782 - 26,420), ml 0.89** 0.91**
Visceral abdominal fat volume (VAV) 3,549 ± 1,842 (491 - 9,825), ml 0.78** 0.81** 0.91**
Subcutaneous abdominal fat volume (SAV) 5,984 ± 3,057 (291 - 18,309), ml 0.87** 0.89** 0.97** 0.78**
Visceral fat percentage (VAV%) 37.2 ± 8.3 (18.1 - 63.3), % -0.16 -0.04 0.05 0.42** -0.17*
Liver density (LD)2 98.7 ± 20.5 (28 - 144), HU -0.71** -0.70** -0.73** -0.71** -0.67** -0.16*
Abbreviations: BMI: Body mass index; CT: Computed tomography; HU: Hounsfield units; SD: Standard deviation.
*: Correlation significant at p<0.05 level; **: Correlation significant at p<0.001 level.
1 BMI data missing for one patient; 2 Liver density data missing for two patients.
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circumference provides quantitative obesity markers 
which are highly correlated with BMI and hepatic CT 
attenuation, which is a marker of steatosis (Table 2). 
To our knowledge, this is the first study of endometrial 
cancer presenting CT-based volumetric quantification 
of the abdominal fat compartments and estimates of 
liver density. Two previous CT studies on 122 [21] 
and 200 [22] EC patients, in which total, visceral and 
subcutaneous fat tissue areas were segmented on a 
single slice at the umbilical level, also showed positive 
correlations between BMI and total (r=0.87/0.67), 
subcutaneous (r=0.86/0.61) and visceral (r=0.75/0.43) 
fat areas (r=Pearson correlation coefficients for the 
two studies, respectively; all p-values <0.001). In 
our cohort, all the CT-derived obesity markers except 
VAV% were associated with low-grade endometrioid 
tumor subtype, which is clinically characterized by 
less aggressive disease. Our results are in line with 
the report by Nakamura et al., except they found no 
association between histological subtype and visceral 
fat area [21].
Liver attenuation values have previously been 
shown to represent a fairly good radiologic estimate of 
hepatic steatosis [23]. We observed that decreasing hepatic 
attenuation was inversely correlated with BMI, TAV, SAV 
and VAV (Figure 1 and Table 2, all p<0.001), and also 
weakly negatively correlated with VAV% (p<0.05). The 
correlation coefficient was slightly stronger for VAV 
(ρ=-0.71) compared to SAV (ρ=-0.67); combined with 
the observed weak negative correlation between VAV% 
and LD (ρ=-0.16) our findings suggest that the visceral 
fat compartment may contribute slightly more than 
subcutaneous fat to obesity-associated hepatic steatosis. 
This is supported by a previous study reporting hepatic 
steatosis to be more closely linked to visceral adipose 
tissue than subcutaneous adipose tissue in healthy women 
[24].
To our knowledge, this is the first study 
presenting data on the relation between hormone 
receptor status in EC and CT-derived preoperative 
obesity markers. Interestingly, all the CT-estimated 
obesity markers except VAV% were associated with PR 
and AR positivity; both markers reportedly associated 
with less aggressive tumors [25, 26]. Furthermore, 
we observed a progressive loss of hormone receptor 
expression with decreasing total body fat (Figure 2), a 
trend that seems predominantly driven by PR loss. The 
present findings are in line with our previous report 
linking obesity to endometrioid histology and positive 
PR status [27]. Surprisingly, no significant association 
was observed between ERɑ status and obesity 
estimates, in spite of the fact that increased estrogen 
signaling is a well-established putative pathogenic 
mechanism in EC development in obese patients. 
This lack of association with ERɑ could be related to 
transcriptionally repressive effects on ERɑ mediated 
by PR signaling. In breast cancer cells, increased level 
of the PR B isoform has been reported to repress both 
ERɑ protein expression and mRNA levels [28] which 
is in line with our finding, but further studies are 
needed to understand the interplay between hormone 
receptor signaling in the setting of obesity in EC.
Figure 1: Low visceral fat percentage is associated with better disease-specific survival and enrichment of immune 
and inflammation related gene sets in endometrial tumors. Abdominal CT scans with segmentation of subcutaneous and visceral 
fat compartments in two patients with comparable BMI measurements, but with different visceral fat percentage (VAV%): (A) Patient 
with BMI 29 and low visceral fat percentage (VAV%=21%). (B) Patient with BMI 30 and high visceral fat percentage (VAV%=62%). (C) 
Kaplan-Meier curve showing significantly reduced disease-specific survival in patients with high VAV% (median cut-off: ≥37%; p=0.005, 
log-rank test). (D) Gene set enrichment analysis of tumors with low (<37%, n=56) versus high (≥37%, n=49) VAV% was performed. 
Diagram shows the percentage of Hallmark and Gene ontology (GO) gene sets enriched in tumors with low VAV% that were linked to 
immunogenic and inflammatory pathways versus other pathways. Cut-off for selected gene sets was False Discovery Rate (FDR) <5%. A 
full description of the gene sets is supplied in Supplementary Table 2.
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Previous reports on the impact of obesity, measured 
by BMI, on endometrial cancer survival are conflicting 
[27, 29-35]. Interestingly, whereas BMI, WC, LD and 
volumetric fat estimates were not associated with survival 
in this cohort, we found that patients with increasing 
visceral fat percentage (VAV%) had significantly reduced 
disease-specific survival, an effect that seemed to be 
independent of BMI (Table 4, Figure 1 and Supplementary 
Figure 2). Notably, disease-specific survival was 
intentionally chosen as end-point, thus ruling out other 
potential causes of early death reportedly linked to a 
high visceral fat proportion; i.e. cardiovascular disease, 
diabetes and other malignancies [11]. Based on the 
present finding, it seems reasonable to hypothesize that 
the metabolic environment induced by a high visceral fat 
proportion may be a driving factor for tumor progression 
and metastasis in endometrial cancer. Similar findings of 
reduced disease-specific survival in patients with high 
visceral fat proportion have been reported for other cancer 
types, including colorectal cancer [14, 15], esophageal 
cancer [13], lymphoma [36] and metastatic melanoma 
[12]. However, the relatively low number of events (n=28) 
in our cohort underlines that the independent prognostic 
impact of VAV% should be interpreted with care, and 
the finding needs to be validated in large independent 
endometrial cancer data sets in future studies. Nonetheless, 
CT-based estimates of abdominal fat volumes and fat 
distribution patterns represent promising biomarkers that 
may yield novel insight into the interplay between the 
metabolic environment and corresponding tumor biology. 
It should also be emphasized that these CT estimates 
are obtainable without much extra time-consume for the 
Table 3: BMI and CT-estimated obesity parameters in relation to clinicopathological factors and hormone receptor 
status for 227 endometrial cancer patients
BMI WC TAV VAV SAV VAV% LD
n (%) median p median p median p median p median p median p median p
(kg/m2) (cm) (ml) (ml) (ml) (%) (HU)
Histological subtype & grade 
(n=225)
0.02 0.02 0.01 0.03 0.01 0.54 0.01
 Endometrioid grade 1-2 152 (68) 28.0 98 10,302 3,647 6,032 37 99
 Endometrioid grade 3 32 (14) 25.2 87 6,645 2,241 4,310 36 109
 Non-endometrioid 41 (18) 25.6 91 7,978 2,849 4,476 39 106
FIGO stage 0.63 0.74 0.90 0.79 0.66 0.21 0.57
 I+II 201 (89) 26.1 96 8,984 3,390 5,613 37 102
 III+IV 26 (11) 26.7 96 8,596 3,160 4,890 40 102
Ploidy (n=119) 0.29 0.30 0.37 0.98 0.19 0.01 0.46
 Diploid 94 (79) 26.4 96 9,438 3,439 5,716 37 99
 Aneuploid 25 (21) 26.1 92 8,024 3,295 4,476 42 102
Age (median) 0.04 0.15 0.35 0.21 0.02 <0.001 0.17
 < 67 years 108 (47) 26.8 96 8,920 3,159 6,084 34 101
 ≥ 67 years 121 (53) 26.4 95 9,174 3,748 5,041 40 102
ERɑ expression, IHC (n=170) 0.36 0.15 0.20 0.23 0.27 0.99 0.10
 Positive 114 (67) 27.1 98 9,627 3,464 5,693 37 100
 Negative 56 (33) 26.0 94 8,152 2,951 4,820 39 105
PR expression, IHC (n=170) <0.001 <0.001 <0.001 0.001 <0.001 0.37 0.002
 Positive 131 (77) 28.0 98 10,386 3,596 6,155 37 100
 Negative 39 (23) 24.6 88 6,180 2,273 3,642 39 106
AR expression, IHC (n=169) 0.01 0.002 0.004 0.004 0.01 0.47 0.01
 Positive 107 (63) 28.0 98 10,420 3,831 6,120 37 98
 Negative 62 (37) 25.1 91 7,957 2,811 4,557 38 106
Abbreviations: AR: Androgen receptor; BMI: Body mass index; CT: Computed tomography; ERɑ: Estrogen receptor alpha; FIGO: International federation of gynecology 
and obstetrics; HU: Hounsfield units; IHC: Immunohistochemistry; LD: Liver density; PR: Progesterone receptor; p: p-values (Independent samples Kruskal-Wallis test for 
histological subtype and grade, remaining p-values: Mann-Whitney U test); SAV: Subcutaneous abdominal fat volume; TAV: Total abdominal fat volume; VAV: Visceral 
abdominal fat volume; VAV%: Visceral fat percentage; WC: Waist circumference.
BMI: data missing for one patient.
Liver density: data missing for two patients.
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radiologist, and could thus quite easily be incorporated 
into the clinic.
Increasing VAV% was significantly associated 
with high age in our cohort. Similar findings were 
reported by Ye et al. [22], and the finding is in line with 
previous literature reporting gradual redistribution of 
fat to the visceral compartment with increasing age in 
healthy individuals [37]. Advanced age is known to be an 
unfavorable prognostic factor in EC [38]. Interestingly, 
when including both age and VAV% in the Cox model, 
only VAV% was an independent predictor of survival. Our 
results could thus suggest that the well-known unfavorable 
prognostic impact of advanced age in EC may in part 
be due to the metabolic effects mediated by the higher 
visceral fat proportion observed in elderly patients.
Although visceral adipose tissue is thought to 
promote carcinogenesis by inducing a state of low-grade 
systemic inflammation [11], we observed an opposite 
trend in tumor tissue: gene sets linked to inflammation 
and immune response were enriched in tumors arising 
in patients with low VAV%, who had better survival 
compared to patients with high VAV%. In line with 
this, high epithelial infiltration of CD8+ T-lymphocytes 
has been reported to be associated with favorable EC 
prognosis [39, 40]. Our finding of improved outcome in 
patients with low VAV%, may thus perhaps be explained 
by a more preserved tumor immune response. Also, in a 
recent study of tumor-bearing mice, systematic physical 
exercise reportedly led to reduced tumor size with 
upregulation of genes associated with immune activity 
[41]. This study also supports the notion that the metabolic 
environment in which a tumor arises may influence host 
defense responses, which may ultimately have an impact 
on tumor growth and patient survival. However, functional 
studies are needed to reveal the relevant mechanisms 
involved, and are necessary if novel targets for treatment 
are to be identified.
This study has some limitations. Our estimates of 
hepatic attenuation were performed on contrast-enhanced 
CT scans which were carried out as a part of the routine 
diagnostic work-up. Although contrast-enhanced CT scans 
have been shown to provide good measures of hepatic 
Figure 2: Total abdominal fat volume in relation to hormone receptor status. Whisker plots displaying the distribution of total 
abdominal fat volumes (L) for 149 endometrial cancer patients. From left to right: tumors with high immunohistochemical expression of the 
estrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) (n=77), low expression of one of the receptors (n=30), low 
expression of two of the receptors (n=21) and low expression of all three receptors (n=21). For each case, positive/negative status for ER, 
PR or AR is indicated by green/red triangles, squares and circles, respectively. * outlier > 1.5 interquartile range, ** outlier > 3 interquartile 
range. P-value: Jonckheere-Terpstra trend test.
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steatosis, non-contrast-enhanced CT is considered slightly 
better and is regarded as the gold standard for evaluation 
of hepatic steatosis [23]. We were not able to adjust for 
alcohol consumption or other potential confounding factors 
related to increased hepatic steatosis since this information 
was not available. Also, our BMI calculations (measured at 
time of diagnosis) and all CT-based estimates only provide a 
snapshot of the metabolic status at one particular time-point 
of the disease. We did not have any data regarding history of 
weight gain/weight loss, or changes in fat distribution over 
time prior to disease development; factors that potentially 
also could be linked to tumor development and survival. To 
be able to better adjust for potential confounding factors, a 
larger study including information for these factors is needed.
In conclusion, this study suggests a negative prognostic 
impact of high visceral fat percentage (VAV%) in EC. Tumors 
arising in patients with low VAV% showed enrichment of 
gene sets related to increased immunogenic and inflammatory 
signaling, thus supporting that the metabolic environment in 
which the tumor arises may influence its immune response. 
Altered tumor immune response in relation to obesity should 
be further explored, and may reveal possible therapeutic 
targets for novel treatment of endometrial cancer patients.
MATERIALS AND METHODS
Patient series
We included 227 women diagnosed with primary 
endometrial cancer between 2009 and 2014 at Haukeland 
University Hospital, Bergen, Norway. The patient 
series was extracted from a larger, population based, 
prospectively collected and well annotated endometrial 
cancer cohort, the Momatec (Molecular Markers in 
Treatment of Endometrial Cancer) study, previously 
well described [25, 42]. All participants signed informed 
consent, and the local ethical committee approved the 
study (REK numbers 2015/2333 and 2009/2315). All 
the included patients had undergone either preoperative 
abdominal contrast-enhanced computed tomography 
(CT) scans (n=225) or non-contrast enhanced CT scans 
(n=2), as part of the routine diagnostic work-up. Primary 
treatment consisted of hysterectomy with bilateral 
salpingo-oophorectomy (HBSO) in 97% of the cases 
(221/227). If HBSO was not performed (6/227), the 
patients were staged based on results from curettage, 
clinical examination and preoperative imaging. All 
patients were staged according to the FIGO 2009 
criteria [43]. Clinicopathological and follow-up data 
were collected by review of the medical records. The 
median follow-up time of survivors was 4.1 years (range 
0.1 – 7.6), and patients were followed from the date of 
primary surgery until December 22nd 2016, or death. 
Histological type was classified as endometrioid or non-
endometrioid, the latter including serous-papillary tumors 
(n=22), clear cell tumors (n=5), carcinosarcomas (n=10) 
and undifferentiated tumors (n=4). BMI was calculated 
from measured height and weight at the time of diagnosis 
(weight in kg divided by height in meters squared). Patient 
characteristics are summarized in Table 1. For a subset 
of the included patients, immunohistochemical data for 
estrogen receptor alpha (ERɑ; n=170), progesterone 
receptor (PR; n=170) and androgen receptor (AR; n=169) 
expression were available, with complete overlap between 
the three hormone receptors for 149 patients. The staining 
procedure and evaluation for ERɑ [44, 45], PR [26] and 
Table 4: Prognostic impact of VAV% adjusted for FIGO stage, age, histological subtype and grade, for 225 
endometrial cancer patients (Cox proportional hazards regression model)
n Unadjusted HR 95% CI p-value Adjusted HR 95% CI p-value
FIGO stage <0.001 0.003
 Stage I 178 1 1
 Stage II 21 1.20 0.27 – 5.26 0.813 0.53 0.11 – 2.59 0.431
 Stage III 21 6.61 2.85 – 15.29 <0.001 4.44 1.75 – 11.26 0.002
 Stage IV 5 11.54 3.31 – 40.31 <0.001 3.11 0.80 – 12.10 0.101
Histological subtype & 
grade <0.001 0.001
 Endometrioid grade 1-2 152 1 1
 Endometrioid grade 3 32 2.22 0.68 - 7.20 0.185 1.12 0.31 - 4.06 0.860
 Non-endometrioid 41 7.59 3.32 - 17.36 <0.001 4.91 1.94 - 12.42 0.001
Age 225 1.05 1.01 – 1.09 0.008 1.02 0.97 -1.07 0.400
VAV% 225 1.07 1.03 - 1.12 0.001 1.05 1.00 - 1.11 0.041
Abbreviations: CI: Confidence interval; FIGO: International federation of gynecology and obstetrics; HR: Hazard ratio; VAV%: Visceral 
fat percentage. p-value: Wald test.
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AR [25] has been described previously. Ploidy status, 
estimated by flow cytometry as previously described [46], 
was available for 119 patients. For 105 patients, fresh 
frozen tissue was available for global gene expression 
analyses, further described below.
Image analyses
Diagnostic abdominal contrast-enhanced CT 
scans (n=225) and non-contrast CT scans (n=2) were 
evaluated for assessment of abdominal fat volume. By 
the software iNtuition (TeraRecon Inc., San Mateo, 
CA, USA), cross-sectional images were analyzed 
consecutively from the upper right diaphragm to L5/S1-
level, using a semi-automated method for volumetric 
quantification of abdominal fat [17]. This method is based 
on segmentation of pixels with values for Hounsfield units 
(HU) corresponding to adipose tissue (-195 to -45 HU) 
[17]. The correct segmentation of the subcutaneous and 
visceral fat compartments was visually verified by the 
operator, and manually adjusted if necessary (Figure 1A 
and 1B). The visceral abdominal fat volume (VAV; cm3) 
and subcutaneous abdominal fat volume (SAV; cm3) were 
estimated. The two compartments were considered to 
comprise the total abdominal fat volume (TAV, cm3). The 
percentage of visceral out of total abdominal fat volume 
([VAV/TAV]x100; VAV%) was also calculated. Waist 
circumference (WC; cm) was measured at the level of 
vertebral body L3/L4.
To estimate liver steatosis as a surrogate marker 
of obesity [3, 20], we used the software ImageJ [47] to 
register attenuation values measured in Hounsfield units 
(HU) on contrast-enhanced images in portal venous 
contrast phase [23]. Mean hepatic parenchymal attenuation 
values were measured in three distinct circular regions of 
interest (ROI) with a diameter of 15 millimeters, and the 
mean value of the three ROIs was calculated and used in 
the analyses. Care was taken to avoid inclusion of visually 
distinct vasculature or biliary ducts, and focal liver 
lesions, if present, in the ROIs. Two patients did not have 
available contrast-enhanced CT scans, and liver density 
measurement was not performed.
Expression microarrays and data analysis
RNA was extracted from fresh frozen tumor 
tissue, and hybridized to Agilent Whole Human Genome 
Microarray Kit, 44k (catalogue number G4 112F) as 
described previously [44]. Arrays were scanned using 
the Agilent Microarray Scanner Bundle. The software 
J-express (www.molmine.com) [48] was used for data 
analysis. Median spot intensity was used to define the 
intensity signal, and the data set was checked for batch 
effects before and after quantile normalization. Gene 
set enrichment analysis (GSEA) (www.broadinstitute.
org/gsea) [49] was performed on the expression data set 
collapsed to max probe (total 30,500 probes), using the 
Molecular Signatures Database (MSigDB, version 5.1) 
datasets Hallmark and c5 (Gene ontology gene sets) 
(www.broadinstitute.org/gsea/msigdb). A false discovery 
rate (FDR) < 5% was set as cut-off level when determining 
significantly differentially expressed gene sets between 
patients with high versus low VAV%.
Statistical analysis
Statistical analyses were performed using SPSS 
(Statistical Package of the Social Sciences), version 
23.0 (IBM Corp, 2015). Correlations were assessed 
by Spearman’s rank correlation (ρ=rho). To compare 
the distribution of a continuous variable between two 
groups, the Mann-Whitney U-test was applied, and 
between multiple groups the Kruskal-Wallis H test or 
Jonckheere-Terpstra trend test was used. For analyses of 
disease specific survival (DSS), patients were included 
at the date of primary surgery, and the primary endpoint 
was defined as death from endometrial cancer. Patients 
who died from other causes were censored at the date 
of death. To examine if any of the obesity variables 
were associated with survival, the Cox Proportional 
Hazards Regression Model was used, after visual 
assessment of included variables by a log-minus-log plot 
to check the assumption of proportional hazards. Only 
univariable significant predictors were included in the 
final multivariable Cox-model. VAV% was dichotomized 
according to median for visual presentation of survival 
data in a Kaplan-Meier plot, assessing survival 
differences between groups by the two-sided log-rank 
test (Mantel-Cox). This dichotomization was also used 
when comparing differentially expressed gene sets 
between groups (high versus low VAV%). All statistical 
tests were two-sided, and p-values less than 0.05 were 
considered significant.
Abbreviations
AR: Androgen receptor; BMI; Body mass index; 
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alpha; FDR: False discovery rate; FIGO: International 
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